Literature DB >> 18355258

Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.

Margaret K Kyle1, Jennifer S Allsbrook, Kevin A Schulman.   

Abstract

OBJECTIVE: To examine the effect of parallel trade on patterns of price dispersion for prescription drugs in the European Union. DATA SOURCES: Longitudinal data from an IMS Midas database of prices and units sold for drugs in 36 categories in 30 countries from 1993 through 2004. STUDY
DESIGN: The main outcome measures were mean price differentials and other measures of price dispersion within European Union countries compared with within non-European Union countries. DATA COLLECTION/EXTRACTION
METHODS: We identified drugs subject to parallel trade using information provided by IMS and by checking membership lists of parallel import trade associations and lists of approved parallel imports. PRINCIPAL
FINDINGS: Parallel trade was not associated with substantial reductions in price dispersion in European Union countries. In descriptive and regression analyses, about half of the price differentials exceeded 50 percent in both European Union and non-European Union countries over time, and price distributions among European Union countries did not show a dramatic change concurrent with the adoption of parallel trade. In regression analysis, we found that although price differentials decreased after 1995 in most countries, they decreased less in the European Union than elsewhere.
CONCLUSIONS: Parallel trade for prescription drugs does not automatically reduce international price differences. Future research should explore how other regulatory schemes might lead to different results elsewhere.

Mesh:

Substances:

Year:  2008        PMID: 18355258      PMCID: PMC2517281          DOI: 10.1111/j.1475-6773.2008.00838.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  7 in total

1.  Cross-national price differences for pharmaceuticals: how large, and why?

Authors:  P M Danzon; L W Chao
Journal:  J Health Econ       Date:  2000-03       Impact factor: 3.883

2.  Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.

Authors:  Mattias Ganslandt; Keith E Maskus
Journal:  J Health Econ       Date:  2004-09       Impact factor: 3.883

3.  Prices and availability of pharmaceuticals: evidence from nine countries.

Authors:  Patricia M Danzon; Michael F Furukawa
Journal:  Health Aff (Millwood)       Date:  2003 Jul-Dec       Impact factor: 6.301

4.  Prices and availability of biopharmaceuticals: an international comparison.

Authors:  Patricia M Danzon; Michael F Furukawa
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

5.  Developing drugs for developing countries.

Authors:  David B Ridley; Henry G Grabowski; Jeffrey L Moe
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

6.  The effect of incentive-based formularies on prescription-drug utilization and spending.

Authors:  Haiden A Huskamp; Patricia A Deverka; Arnold M Epstein; Robert S Epstein; Kimberly A McGuigan; Richard G Frank
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

7.  Employer drug benefit plans and spending on prescription drugs.

Authors:  Geoffrey F Joyce; José J Escarce; Matthew D Solomon; Dana P Goldman
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

  7 in total
  3 in total

1.  Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.

Authors:  Eduard Vrdoljak; Gyorgy Bodoky; Jacek Jassem; Razvan Popescu; Robert Pirker; Tanja Čufer; Semir Bešlija; Alexandru Eniu; Vladimir Todorović; Katerina Kopečková; Galia Kurteva; Zorica Tomašević; Agim Sallaku; Snezhana Smichkoska; Žarko Bajić; Branimir Sikic
Journal:  Oncologist       Date:  2018-09-04

Review 2.  What is the impact of intellectual property rules on access to medicines? A systematic review.

Authors:  Brigitte Tenni; Hazel V J Moir; Belinda Townsend; Burcu Kilic; Anne-Maree Farrell; Tessa Keegel; Deborah Gleeson
Journal:  Global Health       Date:  2022-04-15       Impact factor: 10.401

3.  Overview of external reference pricing systems in Europe.

Authors:  Cécile Rémuzat; Duccio Urbinati; Olfa Mzoughi; Emna El Hammi; Wael Belgaied; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2015-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.